Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkad103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Paul Thoueille und 10 weiteren Autor:innen. Beteiligte Einrichtung: Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Laus…. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swiss HIV Cohort Study, Swiss National Science Foundation.
Abstract (Originalsprache)
Background
Tenofovir alafenamide is gradually replacing tenofovir disoproxil fumarate, both prodrugs of tenofovir, in HIV prevention and treatment. There is thus an interest in describing tenofovir pharmacokinetics (PK) and its variability in people living with HIV (PLWH) under tenofovir alafenamide in a real-life setting.
Objectives
To characterize the usual range of tenofovir exposure in PLWH receiving tenofovir alafenamide, while assessing the impact of chronic kidney disease (CKD).
Methods
We conducted a population PK analysis (NONMEM®) on 877 tenofovir and 100 tenofovir alafenamide concentrations measured in 569 PLWH. Model-based simulations allowed prediction of tenofovir trough concentrations (Cmin) in patients having various levels of renal function.
Results
Tenofovir PK was best described using a one-compartment model with linear absorption and elimination. Creatinine clearance (CLCR, estimated according to Cockcroft and Gault), age, ethnicity and potent P-glycoprotein inhibitors were statistically significantly associated with tenofovir clearance. However, only CLCR appeared clinically relevant. Model-based simulations revealed 294% and 515% increases of median tenofovir Cmin in patients with CLCR of 15–29 mL/min (CKD stage 3), and less than 15 mL/min (stage 4), respectively, compared with normal renal function (CLCR = 90–149 mL/min). Conversely, patients with augmented renal function (CLCR > 149 mL/min) had a 36% decrease of median tenofovir Cmin.
Conclusions
Kidney function markedly affects circulating tenofovir exposure after tenofovir alafenamide administration in PLWH. However, considering its rapid uptake into target cells, we suggest only a cautious increase of tenofovir alafenamide dosage intervals to 2 or 3 days only in case of moderate or severe CKD, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.
- Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
- Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland.
ORCID-Profile: Paul Thoueille, Katharina Kusejko, Perrine Courlet, Matthias Cavassini, Laurent A Decosterd, Thierry Buclin, Monia Guidi
Förderung
- Swiss HIV Cohort Study
- Swiss National Science Foundation
Zitieren
APA
Thoueille, P., Alves Saldanha, S., Desfontaine, V., Kusejko, K., Courlet, P., Andre, P., Cavassini, M., Decosterd, L. A., Buclin, T., Guidi, M., & Swiss HIV Cohort Study (2023). Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad103
Vancouver
Thoueille P, Alves Saldanha S, Desfontaine V, Kusejko K, Courlet P, Andre P, et al. Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad103
BibTeX
@article{Thoueille2023,
author = {Thoueille, Paul and Alves Saldanha, Susana and Desfontaine, Vincent and Kusejko, Katharina and Courlet, Perrine and Andre, Pascal and Cavassini, Matthias and Decosterd, Laurent A and Buclin, Thierry and Guidi, Monia and Swiss HIV Cohort Study, Swiss HIV Cohort Study},
title = {Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkad103}
}
EUVIMED